Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer

Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial

Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation

Immunotherapies for non-small-cell lung cancer and mesothelioma

Phase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells.

Autologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.

WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.

The final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.

Correlation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.

CD40 ligand/interferon-γ matured DC immunization with gp100 antigen HLA class I  A *0201 restricted peptides in patients with newly diagnosed metastatic melanoma.